Inside the Industry

Stay informed with the latest in life sciences. Our News & Insights hub delivers expert perspectives, industry updates, and strategic guidance across the global regulatory, quality, and commercial landscape. From emerging trends to proven strategies, we share the knowledge that drives smarter decisions and faster progress.

All Posts

Press Release: Covita Health Partners Launches with a Mission to Make Expert Life Sciences Consulting More Accessible and Impactful

Covita Health Partners, a newly launched regulatory and quality consulting firm, is proud to announce its entry into the life sciences industry by offering expert, affordable support to innovators developing medical devices, diagnostics, digital health technologies, combination products, human tissue-based therapies, and more. With a focus on accessibility, creativity, and measurable value, Covita is redefining what it means to be a consulting partner in today’s dynamic healt

3 min read

Laboratory Developed Test Final Rule Vacated in Big Win for Clinical Laboratories and Crushing Loss for FDA

The narrative that LDTs are intangible services whereas medical devices are tangible objects has been a core argument from the laboratory industry for decades as they have battled the US Food and Drug Administration (FDA) on their claimed regulatory authority over the tests. FDA has argued that LDTs are indeed tangible objects – the physical instruments that are analyzing the physical patient specimen and providing a test result. Well, the war of definitions has come to an en

3 min read

FDA Publishes Medical Device User Fees for Fiscal Year 2025

On July 31, 2024, the U.S. Food and Drug Administration (FDA) posted a Federal Register notice announcing the Medical Device User Fee Rates for Fiscal Year 2025. The fees have increased by 11.8%, with the exception of the establishment registration fee, which increased by 21.3%.

1 min read

UK MHRA Announces Intention To Recognize Certain International Medical Device Approvals

On May 21, 2024, the United Kingdom’s (UK) Medicine and Healthcare Products Regulatory Agency (MHRA) announced their draft policy for recognizing international regulators’ approvals of medical devices. This stems from their response to the 2021 consultation on the future regulation of medical devices in the United Kingdom, which detailed the intention to introduce alternative routes to market into Great Britain.

5 min read

Tips and Tricks for Responding to a Form FDA 483 to Best Avoid a Warning Letter

FDA’s Office of Regulatory Affairs (ORA) is the lead office for all field activities, including inspections and enforcement. During an inspection, ORA investigators may observe conditions they deem to be objectionable. These observations are listed on a Form FDA 483 when, in an investigator’s judgment, the observed conditions or practices indicate that an FDA-regulated product may be in violation of FDA’s regulations.

4 min read